STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated news page for Bio-Techne (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Techne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Techne's position in the market.

News
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable on February 26, 2024, to all common shareholders of record on February 12, 2024. Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities, generating approximately $1.1 billion in net sales in fiscal 2023 with approximately 3,200 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
dividends
-
Rhea-AI Summary
Bio-Techne's Advanced Cell Diagnostics (ACD) achieves a technical breakthrough with the development of a protease-free RNAscope spatial multiomics workflow, enabling same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology. The new innovation allows for simultaneous imaging of both RNA and protein biomarkers on the same tissue section, providing an unprecedented single-cell view of disease pathology and therapeutic response. The advanced workflow preserves protein and RNA integrity, simplifies image and data analysis, and will be showcased at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced the launch of the first fully automated spatial multiomics workflow, revolutionizing predictive biomarker research and drug development. The solution integrates RNA and protein data at the subcellular level in spatial tissue context without user intervention, offering high throughput and reliable target detection. The multiomics application will be commercially available in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) welcomed presentations from Pfizer and Sanofi at the WCBP conference, showcasing the transformative impact of MauriceFlex™ system on biotherapeutic development processes. MauriceFlex™ offers charge variant characterization and protein size analysis, addressing limitations in traditional methods. Presentations demonstrated its efficiency in AAV gene therapy development and collecting charge variants of complex proteins for downstream mass spectrometry characterization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) has announced a conference call and webcast to review its second-quarter fiscal 2024 financial results. The call is scheduled for February 1, 2024, at 8:00 a.m. CST. Bio-Techne is a leading developer and manufacturer of high-quality purified proteins, reagent solutions, and diagnostic products. The company generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced the appointment of Matthew F. McManus as President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus brings over two decades of senior life sciences leadership experience and will succeed Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has a strong track record in the life sciences industry, having previously served as Executive Vice President and Chief Operating Officer for Azenta and as Senior Vice President and General Manager of Bio-Techne's Molecular Diagnostics Division. He also has a background in gene synthesis and cell & gene therapy markets. Kim Kelderman, Bio-Techne's Chief Operating Officer, expressed excitement for Dr. McManus' return and confidence in his ability to lead the Diagnostics and Genomics Segment through its next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
management
Rhea-AI Summary
Bio-Techne Corporation (TECH) to Showcase Cell and Gene Therapy Solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that Kim Kelderman, current COO, and CEO effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2023 with around 3,100 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) files Drug Master File with FDA for ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that Lunaphore and SIB Swiss Institute of Bioinformatics have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
AI
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

10.49B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Minneapolis

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.